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Abstract
Background: Limited DNA resources or limited DNA
targets in predominant backgrounds for genetic tests
can lead to misdiagnosis. We developed a strategy to
selectively increase the amount of minor targets
through a specific pre-amplification procedure.
Methods: We used the model of circulating cell free
(ccf) male fetal DNA as a minor target in the predom-
inant maternal plasma DNA to evaluate the strategy.
The sex determining region (SRY) locus on the Y
chromosome was used to identify ccf fetal DNA, and
the human glyceraldehydes-3-phosphate dehydro-
genase (GAPDH) gene was used to identify ccf total
DNA in maternal plasma. We selectively pre-amplified
the minor target SRY locus using the Expand Long
Template PCR system and assessed the efficiency of
the pre-amplification by real-time PCR, for both SRY
and GAPDH, to compare the quantities of pre-ampli-
fied fetal DNA with those of maternal total DNA with-
out pre-amplification.
Results: The selected pre-amplification increased the
amount of ccf fetal DNA dramatically (Wilcoxon test:
ps0.000, the fold changes11,596). After selected pre-
amplification, a proportion of 2.19% of the ccf fetal
minor part in the predominant maternal component
was changed up to 25,334%. The increased amounts
of ccf fetal DNA found with the pre-amplification are
not correlated to the amounts found without the pro-
cedure (rs–0.017, ps0.949).
Conclusions: This strategy may be useful in genetic
analysis with limited DNA resources and limited DNA
targets in predominant background molecules. How-
ever, this approach is not suitable for quantitative
assessments, due to the fact that quantitative imbal-
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anced amplification was observed as a result of the
pre-amplification procedure.
Clin Chem Lab Med 2009;47:288–93.
Keywords: genetic analysis; limited DNA resources;
limited DNA target; pre-amplification; quantitative
real-time PCR.
Introduction
Genetic analysis using limited DNA resources, or
limited DNA targets in predominant backgrounds, can
be encountered in many fields of life science (1–3).
For pre-implantation genetic diagnosis, only single
human blastomeres, or first polar body, can be
offered for further analysis (4, 5). In forensic medicine,
the samples obtained are often damaged or degraded
(6). Fine needle aspiration biopsies are minor surgical
procedures for which patient’s specimens for diag-
nosis are obtained (7). However, insufficient material
acquired through these procedures can lead to diffi-
culty in obtaining definitive conclusions.
Recently, the discovery of tissue-derived cell free
and cellular DNA in circulation offers new diagnostic
possibilities in two crucial areas – prenatal genetic
diagnosis (8) and cancer detection (9).
In prenatal medicine, fetal cells and cell free fetal
DNA in maternal blood during pregnancy are poten-
tial sources of fetal genetic material for non-invasive
prenatal diagnosis (10, 11). However, low numbers of
fetal cells in predominant maternal blood cells (12)
and low concentrations of cell free fetal DNA in earlier
gestational ages have limited their use in clinical prac-
tice (13).
In the cancer field, many researchers have attempt-
ed to establish molecular and immunological meth-
ods for the detection of individual metastatic epi-
thelial cancer cells in peripheral blood and bone mar-
row (14–16). However, a human eukaryotic cell con-
taining only one or two copies of each gene has
limited the sensitivity of using genetic alterations as
markers on the DNA level to identify single tumor-
derived cellular and cell free DNA in circulation with
predominant DNA from blood cells.
A strategy of whole genome amplification (WGA)
has been developed to amplify whole genome DNA
for the purpose of increasing the quantity of DNA
molecules (17). However, on the one hand, false allele
generation and imbalance resulting from varying
specificity, sensitivity, and preferential amplification
of alleles can lead to misdiagnosis (18, 19). On the
other hand, WGA may not be suitable for the detec-
tion of rare targets in a predominant background,
such as rare fetal cells in maternal blood (12), as pref-
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erential amplification of background molecules will
make the identification of rare targets more difficult.
In this study, we developed a strategy to pre-ampli-
fy targets selectively according to the aims of genetic
analysis. We used the model of cell free male fetal
DNA in maternal plasma DNA to evaluate the strate-
gy. The sex determining region (SRY) locus on the Y
chromosome was used to identify fetal DNA, and the
human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene was used to identify total circulating
cell free (ccf) plasma DNA, almost representing the
maternal part (12). Using the Expand Long Template
(ELT) PCR kit (Roche Diagnostics GmbH, Mannheim,
Germany), we selectively pre-amplified only the SRY
locus and assessed the efficiency of the pre-ampli-
fication by real-time PCR, for both SRY and GAPDH,
in order to compare the quantities of pre-amplified
fetal DNA with those of maternal total DNA without
pre-amplification.
Materials and methods
This study was performed in the laboratory of Prenatal Med-
icine and Gynecologic Oncology at the University Women’s
Hospital and Department of BioMedicine, University of
Basel, Basel, Switzerland. The study was approved by the
local Ethical Institutional Review Board and informed con-
sent was obtained from all subjects. A total of 17 plasma
samples were collected from pregnant women in the second
trimester with single male fetuses at an average of 21 ges-
tational weeks. Fetal gender was obtained by ultrasound and
confirmed after delivery.
Cell free DNA was extracted from 400 mL plasma using the
QIAmp DNA Mini Kit (QIAGEN GmbH, Hilden, Germany), in
a final elution volume of 100 mL, according to the manufac-
turer’s protocol.
Expand Long Template PCR
The ELT PCR kit (Roche Diagnostics GmbH) was used to pre-
amplify the SRY locus, the rare fetal part in maternal plasma,
according to the manufacturer’s instructions. For each reac-
tion, we used 5 mL of DNA templates, 10 mM of SRY primers
(forward primer: 59-TCC TCA AAA GAA ACC GTG CAT-39;
reverse primer: 59-AGA TTA ATG GTT GCT AAG GAC TGG
AT-39), and 250 mM of each dNTP (Roche Diagnostics
GmbH). ELT enzyme and PCR buffers were used in a final
volume of 25 mL and PCR was performed using a Master-
cycler Gradient (Eppendorf, Basel, Switzerland). The total
PCR cycling profile was as follows: an initial 2 min denatur-
ation at 928C; with the first 10 cycles consisting of a 10-s step
at 928C, a 30-s step at 568C, and a 20-min step at 688C fol-
lowed by another 25 cycles consisting of a 15-s step at 928C,
a 0.5-min step at 568C, and a 20-min step at 688C plus a
20-s increment for each cycle; and a final extension step of
7 min at 688C.
Real-time PCR
The quantities of SRY locus (indicating the cell free fetal
DNA), with and without the ELT PCR procedure, and the
quantity of GAPDH sequences (indicating the cell free mater-
nal background DNA) from the 17 samples were assessed
using the ABI PRISM 7000 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA). Extracted DNA
(5 mL) without the ELT PCR procedure for SRY and GAPDH
quantifications, and 5 mL of 1–10 diluted ELT PCR products,
after the ELT PCR procedure for SRY quantification, were
used as the templates for real-time PCR.
The above-mentioned primers for SRY were reused, and
the probe for SRY was 59 (VIC) TCC CCA CAA CCT CTT (MGB)
39.
The primers and the probe for GAPDH were as follows:
Forward primer: 59-CCCCACACACATGCACTTACC-39,
Reverse primer: 59-CCTAGTCCCAGGGCTTTGATT-39, and
Probe: 59-MGB-TAGGAAGGACAGGCAAC–FAM-39.
For the PCR assay, we used a reaction volume of 25 mL,
containing 5 mL of template, primers at a concentration of
300 nM, a probe at 200 nM, and 12.5 mL of 2=TaqMan
Master Mix (Applied Biosystems, Branchburg, NJ, USA).
Each sample was measured in duplicate.
The reaction was performed at the following conditions: a
first denaturation step at 958C for 10 min, and 40 cycles of
1 min at 608C, followed by 15 s at 958C (12).
Data collection
We obtained the threshold cycle (Ct) values output from the
ABI Prism 7000 software. The quantities of SRY and GAPDH
were calculated using standard dilution curves generated
from a known concentration of a male human genomic DNA,
ranging from 3.125=104 to 10 pg/mL (including 31,250, 6250,
1250, 250, 50, and 10 pg/mL). The results were expressed as
genome-equivalent (GE) per mL of plasma by using the
conversion factor of 6.6 pg of DNA per cell (20). The fold
change of SRY, with and without the ELT PCR procedure,
was estimated using a simple equation: mean-SRY with ELT/
mean-SRY without ELT. The proportion of fetal SRY in the total
GAPDH was obtained using a similar equation: mean-SRY/
mean-GAPDH=100%).
Statistical analysis
The data analysis was performed using SPSS software
(Statistical Software Package for Windows, v15.0, SPSS Inc.,
Chicago, IL, USA). The Shapiro-Wilk test and the Kolmogo-
rov-Smirnov test were used to analyze the normality. The
two tests showed that our dataset was not normally distrib-
uted (ps0.000/0.000 with the Shapiro-Wilk test, and
ps0.000/0.001 with the Kolmogorov-Smirnov test for the
SRY assay and the GAPDH assay, respectively). The Wil-
coxon test was used to compare the significance of quanti-
ties with and without the ELT PCR procedure, and the
Spearman test was applied to investigate the correlations
between SRY quantities with and without the ELT PCR pro-
cedure, as well as between SRY and GAPDH quantities.
Results
The quantities of ccf fetal DNA (SRY) and ccf maternal
DNA (GAPDH) are given in Table 1 as mean, median,
range, and fold change. The correlation analyses are
also available in Table 1.
Our data show that without the ELT PCR procedure,
ccf fetal SRY DNA is present in maternal plasma with
a mean of 150 GE/mL (range 36–484), and the total
ccf GAPDH DNA is present in a higher concentration
of 6866 GE/mL (range 298–43,071). The concentration
of the fetal part in the maternal background corre-
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Table 1 Quantification and correlation analysis for GAPDH and SRY assays.
SRY, GE/mL GAPDH, GE/mL SRY/GAPDH Correlation
Without ELT 150 (mean) 6866 (mean) 2.19% rs0.061
117 (median) 3180 (median) ps0.815
(36–484) (298–43,071)
With ELT 1,739,441 (mean) ND 25,334% rs–0.135
427,979 (median) ps0.605
(8231–6,211,450)
Fold change 11,596 ND 11,568 No
Correlation rs–0.017 ND No No
ps0.949
Figure 1 Boxplot: significantly higher amounts of pre-amplified SRY compared to those without pre-amplification.
sponds to 2.19%. With the ELT PCR procedure, the
quantities of ccf fetal DNA are dramatically increased
with a mean of 1,739,441 (range 8231–6,211,450)
(Wilcoxon test: ps0.000) (Figure 1). The fold change
of pre-amplified SRY, compared to that without pre-
amplification, totals more than 10,000. The 2.19% of
the minor fetal part in the predominant maternal part
was changed up to 25,334%. Also, more than a
10,000-fold change is obtained. Figure 2A shows an
example of the increase in fetal SRY after the pre-
amplification in the total GAPDH quantities, and Fig-
ure 2B shows the comparison of the Ct value of SRY
with and without pre-amplification. The amount of the
SRY was increased 2048-fold after selected pre-
amplification. It is an output of a delta Rn vs. cycle
from the 7000 SDS. The parameter Ct is defined as
the fractional cycle number at which the fluorescence
passes the fixed threshold. The high amount of start-
ing SRY after pre-amplification (the earlier lines)
shows that the increase takes place sooner in fluores-
cence than it does in the GAPDH reaction (the later
lines).
From the dataset, we did not find any correlation
between ccf fetal DNA and ccf maternal DNA. No rela-
tionships in the quantification between the treatments
with and without ELT PCR procedure were observed,
suggesting that the pre-amplification was quanti-
tatively imbalanced (Figure 3).
Discussion
In this study, we intended to develop a selected pre-
amplification strategy according to pre-amplify-spe-
cific targets that may be useful in the cases of using
limited DNA resources and limited DNA targets in
predominant background molecules. We designed
the rare ccf fetal SRY DNA in maternal plasma as the
minor target, and the rich ccf maternal GAPDH DNA
as the predominant background component. We used
the ELT PCR system to specifically pre-amplify the
minor fetal SRY sequence separately. The efficiency
of the pre-amplification was assessed by real-time
PCR.
291 Xia et al.: Selected pre-amplification of specific DNA targets
Article in press - uncorrected proof
.
Figure 2 Comparison of PCR efficiency with and without
pre-amplification.
(A) The Ct value of GAPDH (originally representing the pre-
dominant maternal component) without pre-amplification
and the Ct value of pre-amplified SRY (originally represent-
ing the minor fetal target). The amounts of the minor part
were increased dramatically after selected pre-amplification.
(B) The comparison of the Ct value of SRY with and without
pre-amplification. The amount of the SRY was increased
2048-fold (2DCTs11) after selected pre-amplification.
Figure 3 Correlation study between the amounts of SRY, with and without pre-amplification.
The x-axis represents the quantities of SRY without pre-amplification. The y-axis represents the quantities of SRY with pre-
amplification. Scatter plots show no significant correlation between the amount of SRY with and without pre-amplification
(rs–0.017, ps0.949).
Our data show that the procedure could increase
the minor target dramatically. A fold change of more
than 10,000 after pre-amplification could be obtained.
We believe that the strategy may be useful in fields,
such as single cell genetic diagnosis, testing damaged
or degraded DNA samples, and fine needle aspiration
biopsies, etc., for which only limited DNA recourses
may be available. Compared to the traditional nested-
PCR (21), using our pre-amplification, a nested primer
pair is not needed. Furthermore, the ELT PCR system
used in our study, according to the function of the
enzyme included in the system, enables amplification
of long templates. Compared to the traditional whole
genome pre-amplification, selected pre-amplification
according to the aim of the tests may minimize false
allele generation and imbalances resulting from vary-
ing specificity, sensitivity, and preferential ampli-
fication of alleles leading to misdiagnosis.
In our study, the proportional relationship between
the minor fetal target and predominant maternal com-
ponent was changed from 2.19% up to 25,334%
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through the pre-amplification, suggesting that the
procedure is especially suitable for cases of minor tar-
gets in predominant background components, such
as fetal cells and ccf fetal DNA in maternal circulation
for non-invasive prenatal diagnosis. Non-invasive
prenatal diagnosis can be hampered by the limited
amounts of fetal genetic materials in maternal circu-
lation, especially in early gestational ages (13, 22).
Using our strategy, fetal genetic materials in maternal
circulation, such as the fetal SRY (for the diagnosis of
X-linked diseases) and the fetal RhD in the circulation
of RhD positive pregnant women (for the manage-
ment of RhD-incompatibilities) (10), which are absent
from the maternal genome, can be easily selectively
pre-amplified, as shown in this study on ccf fetal SRY
assay.
For detecting subtle mutations in minor fetal com-
ponents or minor pathological components, which
only differ slightly from the wild-type DNA of interest,
a designed peptide nucleic acids clam may be useful
to suppress the amplification of the wild-type mole-
cules in the pre-amplification procedures. The clam
can be designed to bind to the wild-type allele with
very high affinity specifically. In our group, we devel-
oped the approach for non-invasive prenatal diagno-
sis of paternally inherited mutations (23).
In our study, we compared different protocols for
the selected pre-amplification using different PCR
enzymes and buffers, such as TaqMan Master Mix
(data not shown). The best results were obtained by
using the ELT PCR system. For the pre-amplification,
we set up cycling profiles according to the manufac-
turer’s instructions. The cycling profiles could be
shortened, if the templates selected for pre-amplifi-
cation were not long.
We described a strategy to increase the DNA tar-
gets selectively by a specific pre-amplification. This
strategy was confirmed by a model using ccf fetal
SRY as a minor target in the predominant maternal
DNA components. This approach is easy to perform,
and it may minimize the false allele generation due to
using selected pre-amplification, rather than whole
genome pre-amplification. It may be useful in genetic
analysis with limited DNA resources and limited DNA
targets in predominant background molecules,
according to the aim of the applications. However,
this approach is not suitable for quantitative assess-
ments, due to the fact that quantitative imbalanced
amplification resulting from the pre-amplification pro-
cedure was observed in our study.
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